Oxford BioTherapeutics Partners with GSK to Advance Novel Cancer Therapies
Written by Emily J. Thompson, Senior Investment Analyst
Source: Globenewswire
Updated: 51 minutes ago0mins
- Strategic Collaboration: Oxford BioTherapeutics (OBT) has entered a multi-year strategic collaboration with GSK to leverage OBT's OGAP®-Verify platform for identifying multiple novel oncology targets, aiming to develop first-in-class antibody-based cancer therapeutics, showcasing OBT's strong potential in oncology innovation.
- Financial Support: Under the agreement, OBT will receive an undisclosed upfront payment from GSK and may be eligible for downstream milestone payments and royalties on net sales, providing crucial funding to support OBT's research and development pipeline.
- Technological Advantage: OBT's OGAP®-Verify platform enhances target identification sensitivity and specificity, supporting the development of differentiated antibody-based therapies, which not only boosts OBT's R&D capabilities but may also accelerate the time-to-market for new drugs, addressing unmet patient needs.
- Market Outlook: This collaboration marks OBT's second major partnership with a leading global pharmaceutical company this year, reflecting its growing influence in cancer research and is expected to enhance OBT's competitiveness and market share in the global biopharmaceutical landscape.
OBT.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on OBT
Wall Street analysts forecast OBT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OBT is 29.00 USD with a low forecast of 29.00 USD and a high forecast of 29.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 27.250
Low
29.00
Averages
29.00
High
29.00
Current: 27.250
Low
29.00
Averages
29.00
High
29.00
Hovde Group
NULL
to
Outperform
initiated
$30.50
2025-05-12
Reason
Hovde Group
Price Target
$30.50
2025-05-12
initiated
NULL
to
Outperform
Reason
Hovde Group initiated coverage of Orange County Bancorp with an Outperform rating and $30.50 price target.
Piper Sandler
Mark Fitzgibbon
Buy
Maintains
$66 → $71
2024-12-13
Reason
Piper Sandler
Mark Fitzgibbon
Price Target
$66 → $71
2024-12-13
Maintains
Buy
Reason
See All Ratings
About OBT
Orange County Bancorp, Inc. is a bank holding company. Through its wholly owned subsidiaries, Orange Bank & Trust Company, a New York state-chartered trust company (the Bank) and Orange Investment Advisors Inc., an investment advisor (HVIA), the Company offers full-service commercial and consumer banking products and services and trust and wealth management services to small businesses, middle-market enterprises, local municipal governments and individuals in the Lower Hudson Valley region, the New York metropolitan area and nearby markets in Connecticut and New Jersey. Its segments include Banking and Wealth Management. The Banking segment involves the delivery of loan and deposit products to its customers through the Bank. The Wealth Management segment, which includes asset management and trust services to individuals and institutions through HVIA and the Bank that provides trust and investment management fee income in its wealth management business segment.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?